Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Mosaic Trial for Stem Cell Transplant Recipients

NCT06960993 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recruited prior to their scheduled transplant, then randomized to use one of these two study websites throughout the study. They will complete five assessments during the study: one before transplant (baseline) and four after transplant (2, 4, 6, and 8 month follow-ups). The main questions this trial aims to answer are: 1. Compared to patients using the control group website, do patients using the intervention website report greater improvements in general psychological distress, cancer treatment-related distress, physical symptoms, and health-related quality of life? 2. Are these benefits at least partially explained by improvements in perceived preparedness, self-efficacy, and approach coping and/or reductions in avoidant coping and perceived stress? 3. Do some patients benefit more from using the intervention website than others? Specifically, we will examine whether patients' primary language (English/Spanish) and their initial psychological distress are related to the benefit they get from using the intervention website. We will also explore effects of sex, race, ethnicity, and transplant type.

Interventions

  • BEHAVIORAL Intervention website
  • BEHAVIORAL Enhanced Usual Care (Control) Website

Study Locations (3)

District of Columbia

  • Georgetown University School of Medicine — Washington D.C.

Illinois

  • Northwestern University Feinberg School of Medicine — Chicago

New Jersey

  • Hackensack Meridian Health — Nutley

Trial Details

FieldValue
Enrollment Target 356 participants
Start Date 2025-04-28
Est. Completion 2030-02-01
Phase NA

Sponsor

Northwestern University

1,033 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06960993

The ClinicalTrials.gov registry entry for NCT06960993 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 356 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,033 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 7 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions — of which Intervention website is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06960993 reports 3 study locations spanning 3 distinct geographic areas — top geographies include District of Columbia, Illinois, New Jersey. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06960993 about?

NCT06960993 is a clinical study titled "Mosaic Trial for Stem Cell Transplant Recipients". The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recrui...

What is the current status of trial NCT06960993?

This trial is currently recruiting. It is a NA study. The enrollment target is 356 participants. The study started on 2025-04-28. Estimated completion is 2030-02-01.

What conditions does trial NCT06960993 study?

This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Leukemia, Myelodysplastic Syndromes, Hematologic Malignancy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06960993?

The interventions under investigation include: Intervention website (BEHAVIORAL), Enhanced Usual Care (Control) Website (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06960993?

This trial is sponsored by Northwestern University, which has 1,033 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06960993 being conducted?

This trial has 3 study locations across District of Columbia, Illinois, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial